The CORRECT Trial, of regorafenib monotherapy for previously treated mCRC [4]; the RECOURSE Trial, of TAS-102 for refractory mCRC [5]; the TERRA phase III trial, of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated mCRC [6]; the FRESCO Trial, of the effect of fruquintinib compared with placebo on OS in patients with previously treated mCRC [7]; the CONCUR trial, of regorafenib plus best supportive care versus placebo in Asian patients with previously treated mCRC [11]; ECOG PS – Eastern Cooperative Oncology Group Performance Status; EGFR – epidermal growth factor receptor; VEGFR – vascular endothelial growth factor receptor; Reg – regorafenib; Fruq – fruquintinib; TAS – TAS-102; NR – not reported; PLA – placebo.
*  The RECOURSE Trial [5] enrolled some patients previously treated with regorafenib (17% patients in the TAS-102 group, and 20% patients in the placebo group).